SynapCell

INNOVATIONs 
Pipeline

state-of-the-art translational research

Our Research & Innovation scientists carry out intensive research to discover novel EEG biomarkers of brain disorders, which will become available for further compound testing.

Check out our process below and view our latest progresses.

Willing to collaborate on a project?

Join our Open Innovation Program.
Step
1
CLINICAL STATE-OF-THE-ART

Intensive review of clinical litterature to find out which EEG signatures have been identified in human patients with brain diseases.

Exchanges with physicians on their clinical practice and review of protocols, pharmacology and data.

Step
2
CLINICALLY-RELEVANT MODEL

Identification and selection of appropriate animal model from litterature, collaborations. Animal modeling.

Step
3
MODEL PHENOTYPING

Rodent model Phenotyping by EEG, LFP, ecoG: It is possible to phenotype a model you find relevant for your research, either from your lab or from a third-party provider.

Step
4
Oscillatory signatures identification

Does the brain of the model express EEG signatures that are specific to the disease and similar to patterns found in human patients?

Step
5
PHARMACOLOGICAL CHALLENGE

Validation of the oscillattory signature's robustness with a pharmacology of reference (if it exists). In case of success, the oscillatory signature can be used as a surrogate biomarker of the disease.

Step
6
BIOMARKER VALIDATION

Additional battery of tests are carried out to confirm the robustness of the biomarker. That include increase of animal cohort size, more pharmacological challenges and deeper statistical analysis.

Step
1
CLINICAL STATE-OF-THE-ART
Step
2
CLINICALLY-RELEVANT MODEL
Step
3
MODEL PHENOTYPING
Step
4
Oscillatory signatures identification
Step
5
PHARMACOLOGICAL CHALLENGE
Step
6
BIOMARKER VALIDATION

INNOVATING RESTLESSLY
TO PUSH THE BOUNDARIES OF NEUROSCIENCES

Let's talk about your next project